Analyst Ratings for Silver Standard Resources Inc. (SSRI)Updated: 2017-07-27
Silver Standard Resources Inc. (NASDAQ:SSRI) was awarded an average rating of Overweight from investment analysts following the stock. About 30 days ago, SSRI was issued an average rating of Overweight.
Of the 10 analysts covering the stock, 5 gave it a buy rating, 1 issued an overweight rating, 4 issued a hold rating, 0 issued an underweight rating, and 0 issued a sell rating. Over the past 90 days, the number of analysts that are bullish on the stock has increased by 1. During this time, the number of analysts bearish on the stock has increased by 0.
Several price targets were given for SSRI by the analysts covering the stock. The highest price target was 17.26, implying a possible profit of 80.53 percent. The most pessimistic analyst gave a price target of 10.56, implying potential capital losses of 10.45 percent. It is advisable to not rely only on price targets or ratings, as these can be biased for some stocks.
In the last 30 days, analysts have changed their quarterly earnings estimates downwards by an average of -0.89 percent. The average change in earnings estimates over the last 90 days is 0 percent. Over the past 30 days, FY earnings estimates have also changed downwards by -12.57 percent. If we look at the last 90 days instead, we find a net average change of 0 percent in FY estimates.
Investors like to see analysts making revisions in the same direction, as that raises confidence in the revisions. 0 analysts have revised their quarterly estimates upwards in the past 30 days, which can be compared to the 2 analysts that decreased their estimates. Also over the last month, 0 analysts increased their estimates for the FY earnings, while 2 analysts made negative revisions to their fiscal year's estimates.
The growth rate of SSRI's earnings is estimated by analysts to be -53.99 percent. Another measure frequently examined by investors is the PEG ratio. Smaller PEG ratios are desirable, as that can indicate whether the high price level of a stock is warranted by high growth. Wall Street investors typically prefer a PEG ratio to be smaller than 1, even though it may be more relevant to compare the ratio to that of a firm's competitors. SSRI has a PEG ratio of -0.27.
SSRI has traded between a high of 15.84 and a low of 7.70 over the past year. Today's price is 24.17 percent above the 52-week low, and 39.64 percent below the high. SSRI has a P/E ratio of 14.59. Investors typically compare the P/E ratio to a company's peers in the industry. The SSRI value stock report compares SSRI to some of its peers using value stock charts. The market cap of SSRI is $1.17 billion. SSRI's next earnings release will be on 0000-00-00, which is days away.